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Abstract
Background: Patients with type 2 diabetes (T2DM) are at increased risk for macrovascular events as well as for
microvascular complications. There is evidence that in patients with coronary artery disease (CAD), about 35 %
suffer from manifest T2DM. Early glucose-lowering intervention in subjects with T2DM has been demonstrated to
be beneficial in terms of cardiovascular risk reduction. But thus far, no data are available regarding investigating the
impact of linagliptin treatment in patients with early diabetes on cardiovascular endpoints or surrogate parameters.
Therefore, the aim of this study is to investigate the effects of linagliptin in CAD patients with early T2DM on
various cardiovascular surrogate measurements including mechanical and biochemical endothelial function
assessments.
Methods/design: Forty-two subjects with early diabetes and CAD are included in this investigator-driven,
randomized, placebo-controlled, double-blind, phase IV, single-center study. Participants will be randomized to
receive either linagliptin (5 mg) administered once daily per os or placebo for 12 weeks. Before and after the
intervention, evaluation of endothelial function (flow-mediated dilatation and biochemical biomarkers) and a Meal
Tolerance Test are performed.
Discussion: Cardiovascular surrogate parameters, such as endothelial function, are able to provide insights into the
potential mechanisms of the cardiovascular effects of antihyperglycemic agents. Currently ongoing trials do not
specifically focus on early diabetes as a target of intervention and we therefore believe that our study will contribute
to a better understanding of the cardiovascular effects of dipeptidylpeptidase-4 (DPP-4) inhibitors in early diabetes.
Trial registration: NCT02350478. Registered 26 January 2015. Protocol date/version 24 October 2014/version 2.4
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Background
Patients with type 2 diabetes (T2DM) are at increased
risk of macrovascular events as well as of microvascular
complications [1]. It is well-known that the pathophysio-
logic process of T2DM starts many years before the
diagnosis can be made on the basis of elevated fasting
blood glucose or pathologic glucose tolerance evaluation
[2], and in particular the data from the United Kingdom
Prospective Diabetes Study (UKPDS) and the UKPDS
post-trial monitoring highlighted the importance of an
early glucose-lowering intervention in patients with
T2DM for the reduction of future microvascular and
macrovascular complications [3, 4]. We [5, 6], and in
particular the Euro Heart Survey on Diabetes and the
Heart [7], have demonstrated that disturbances of glu-
cose metabolism are present in approximately two thirds
of patients with CAD, and current joint guidelines of the
European Society of Cardiology (ESC) and the European
Association for the Study of Diabetes (EASD) recom-
mend screening for dysglycemic states in this patient
population [8].
Dipeptidylpeptidase-4 (DPP-4) inhibitors increase en-
dogenous glucagon-like peptide-1 (GLP-1) levels and
GLP-1 in turn increases insulin release from pancreatic
beta cells in a glucose-dependent manner as well as sup-
pressing glucagon secretion from pancreatic alpha cells.
Investigations in T2DM patients have shown that this
drug class lowers both fasting and postchallenge or post-
meal glucose levels, and hence glycosylated hemoglobin
(HbA1c), and is well-tolerated.
However, the lowering of the surrogate measurement
HbA1c level has not necessarily turned out to translate
into a reduced number of cardiovascular events in
patients with T2DM and, therefore, the American Food
and Drug Administration (FDA) [9] and the EMA
(European Medicines Agency) [10] issued in 2008 and
2010, respectively, guidance for new glucose-lowering
drugs, requiring at least the proof of cardiovascular
safety. Three cardiovascular outcome trials with the
DPP-4 inhibitors alogliptin, saxagliptin and sitagliptin
have been published to date [11–13] and have demon-
strated cardiovascular safety albeit not cardiovascular
superiority to usual diabetes care without DPP-4 inhibi-
tors. Two outcome trials with linagliptin (CAROLINA
[14] and CARMELINA - NCT01897532) are underway,
of which the former is performed in subjects with early
diabetes.
A major limitation of the published studies is that they
included primarily patients with longstanding diabetes
(median duration of between 7.1 and 11.6 years in
EXAMINE, SAVOR-TIMI53 and TECOS) while data
from the UKPDS suggest that patients benefit most from
an early glucose-lowering intervention rather than a
later intervention in the course of the disease. The
cardiovascular impact of DPP-4 inhibitors in early treat-
ment remains unclear and there is currently no ongoing
trial in this patient population given the low event rate
and the need for long-term follow-up.
A well-known and validated cardiovascular surrogate
parameter for future cardiovascular events is endothelial
dysfunction. We and others have shown previously that
endothelial dysfunction is present in patients with CAD
and early diabetes and can be improved by pharmaco-
logic intervention [15, 16]. Data on the effect of DPP-4
inhibitors on endothelial function are sparse and the re-
sults of these trials are conflicting. While Nakamura et
al. [17] demonstrated an improvement of endothelial
function with sitagliptin, Ayaori and coworkers [18]
showed a worsening of endothelial function with the
same drug. However, none of these trials was performed
in a placebo-controlled fashion.
Therefore, we aim to perform a randomized, placebo-
controlled, double-blind trial investigating the effect of
the DPP-4 inhibitor linagliptin on endothelial function
and further biochemical markers of vascular function,
which will help to better understand the cardiovascular
effects of DPP-4 inhibitors in early diabetes.
Aim of the study
The aim of our current study is to investigate the ef-
fects of linagliptin in CAD patients with early T2DM
on various cardiovascular surrogate measurements in-




This is an investigator-driven, prospective, randomized,
placebo-controlled, double-blind, phase IV, single-center
study to evaluate the effect of linagliptin 5 mg once
daily on cardiovascular surrogate measures in patients
with early diabetes and CAD (Fig. 1). The trial was
approved by the Ethics Committee of the Medical
University of Graz (25-295 ex 12/13) and is con-
ducted at the Division of Endocrinology and Diabetol-
ogy at the Medical University of Graz (academic
hospital), Austria. All participants are asked to pro-
vide written informed consent before entering the
study. Clinical trial authorization has been obtained
from the Austrian Agency for Health and Food Safety
(AGES) (EudraCT number: 2013-000330-35). Import-
ant protocol modifications will be reported to the
local Ethics Committee of the Medical University of
Graz and, if necessary, to the AGES. This study
follows the international recommendations for inter-
ventional trials (see the Standard Protocol Items: Rec-
ommendations for Interventional Trials (SPIRIT)
checklist in Additional file 1).
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Inclusion and exclusion criteria
Participants for the trial are aged 40 to 80 years with
early T2DM (i.e., 2-h glucose post oral glucose exposure
(75 mg) > 200 mg/dl or T2DM treated with diet only or
on a stable dose of metformin monotherapy), a recent
glycosylated hemoglobin (HbA1c) level of between 6.0
(42 mmol/mol) and 9.0 % (75 mmol/mol) and coronary
atherosclerosis (diagnosed either by coronary angiog-
raphy or coronary computer tomography).
The exclusion criteria are: acute coronary syndrome or
a cerebrovascular event within the previous 4 weeks;
Body Mass Index (BMI) > 35.0 kg/m2; serum creatinine
level > 2.5 mg/dl; aspartate aminotransferase (AST)/ala-
nine aminotransferase (ALT) more than threefold the
upper limit of normal; heart failure more severe than
NYHA class II; uncontrolled hypertension (blood pres-
sure above 165/100 mmHg); treatment with orally
administered steroids; use of a new-onset statin or
angiotensin converting enzyme (ACE) inhibitor within
the previous 6 weeks; known malignancy; known intoler-
ance to DPP-4 inhibitors; any antidiabetic therapy except
metformin; and pregnant or breastfeeding women. We
amended the reduction of the lower boundary of the
range of HbA1c level from 6.5 (48 mmol/mol) to 6.0 %
(42 mmol/mol) after the enrollment of 10 subjects to
increase the recruitment rate.
Primary objective
The primary objective of this trial is to determine
whether 12-week linagliptin treatment is associated with
an improvement in endothelial function in patients with
early diabetes.
Secondary objective
1. To investigate the effect of linagliptin treatment on
arginine bioavailability ratios (global arginine
bioavailability ratio (GABR) and arginine to
ornithine ratio)
2. To study the impact of linagliptin treatment on
biochemical markers of endothelial function (soluble
vascular cell adhesion molecule-1 (sVCAM-1) and
soluble intercellular adhesion molecule-1 (sICAM-1)
3. To evaluate the Area Under Curve (AUC) of
glucose, insulin and free fatty acids (FFA) during
the Meal Tolerance Test (MTT)
Outcome measurements
The primary outcome is the difference in endothelial
function measured by FMD (flow-mediated dilatation)
before and after 12 weeks of treatment with linagliptin
or matched placebo.
The secondary outcome measures are GABR, arginine
to ornithine ratio, sVCAM-1 level, sICAM-1 level and
AUC of glucose, insulin and FFA during the MTT.
Interventions
The subjects receive either linagliptin 5 mg (licensed
dose for treatment of T2DM) or matched placebo tables
administered per os once daily for 12 weeks. The drug
Fig. 1 Flow diagram of the study design (*study dropouts will be replaced)
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and placebo are supplied by Boehringer Ingelheim as
bulkware study medication. The study capsules, lina-
gliptin and placebo are identical in appearance and all
are tasteless and colorless. The pharmacy at the Med-
ical University of Graz, Austria packs the medication
as 12-week supplies for study participants and labels
the study medication according to current regulatory
requirements.
Patients are asked not to adjust their antidiabetic treat-
ment during the study period. However, if glycemic con-
trol appears to be inappropriately high during these
12 weeks, additional glucose-lowering drugs may be
used at the discretion of the principal investigator. Un-
less contraindicated, the first choice for rescue medica-
tion should be a sulfonylurea.
The subjects are instructed to return all unused or
partly-used medication and packaging from medication
at the follow-up visit. Tablets are counted at the end of
the 12 weeks of the treatment period to verify medica-
tion adherence. Significant nonadherence is defined as
missing 20 % or more doses of trial medication during
the 12 weeks of the treatment period. In the case of
study medication noncompliance, participants would
continue to be followed to their last visit. These data
would not be part of the per-protocol analysis but would
form part of an intention-to-treat (ITT) analysis.
Withdrawal of consent and major protocol violations
will lead to an early study termination for the subject
Eligibility and recruitment
The study population will consist of 48 subjects with
early diabetes and CAD. Subjects are identified from the
outpatient clinic at the Department of Endocrinology
and Diabetology, the Division of Cardiology, via primary
care and advertisements. The clinic staff informs pa-
tients about the possibility of being enrolled in this
study. No study-related procedures are undertaken be-
fore obtaining informed consent. Then, the study team
explains the study procedures in detail and asks the par-
ticipant about their willingness to participate in this re-
search study. After informed consent is signed and
obtained, participants are given a signed copy of the In-
formed Consent Document and are assigned a screening
identification number. Any use of study samples that is
outside the scope of the objectives of this protocol will
be submitted for prior review and approval by the ap-
propriate Institutional Review Board.
Screening
Screening of participants consists of the evaluation of
inclusion and exclusion criteria. After informed consent
is obtained, a numbered subject folder is created for
potential participants, including information about
medical history, physical examination and their actual
medication. Glycosylated hemoglobin (HbA1c), serum
creatinine and AST/ALT levels obtained from venous
blood are checked by laboratory investigation. Women
of reproductive potential undergo urine pregnancy test-
ing. Eligible subjects are scheduled for the following
study visits (Table 1).
Randomization and blinding
Participants are randomized to one of the two study arms
(intervention versus placebo) in the ratio 1:1 in real time
by using the web-based randomization tool “Randomizer
for Clinical Trials” (https://www.randomizer.at/). The soft-
ware’s compliance with Good Clinical Practice (GCP) has
been confirmed by the Austrian Agency for Health and
Food Safety (AGES). The randomization plan is designed
by the Institute of Medical Informatics, Statistics and
Documentation, Medical University Graz, Austria, which
passes the treatment codes to the Pharmacy of the Univer-
sity Hospital Graz for adequate labeling and blinding of
the medication. The labels of the study medication display
the name of the trial, the name of the investigational me-
dicinal product and contact details of the principal investi-
gator. Subject numbers are assigned sequentially as each
subject enters the study. The study is subject- and
investigator-blinded during the treatment periods from
visit 2 until the end of the study. In the rare case of a re-
quirement to unblind study medication, the principal in-
vestigator needs to give permission for unblinding. The
unblinding list is held by the Institute of Medical Inform-
atics, Statistics and Documentation, Medical University of
Graz, which is not involved in study investigations.
Reporting procedure for all adverse events
All adverse events (AE), serious (SAE) and nonserious,
are collected, documented and reported on the appropri-
ate Case Report Forms (CRFs)/SAE Reporting Forms
once informed consent has been signed and this will end




Start date of event




Relationship to study drug (i.e., causality/relatedness)
Assessment of relatedness to other suspect drug
or device
Action taken with study drug
Whether subject withdrawn due to an adverse event
Whether the event is serious
Follow-up information will be recorded as necessary
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Table 1 Schedule of enrollment, interventions and assessments
sVCAM-1 Soluble Vascular Cell Adhesion Molecule-1, sICAM-1 soluble Intercellular Adhesion Molecule-1
Tripolt et al. Trials  (2016) 17:495 Page 5 of 9
AEs considered to be related to study medication as
judged by a medically qualified investigator are followed
until resolution or the event is considered stable. All re-
lated AEs that result in a subject’s withdrawal from the
study or are present at the end of the study are followed
up until a satisfactory resolution occurs.
Reporting procedure for serious adverse events
The investigator reports any SAEs and nonserious AEs
which are relevant for reported SAEs and AEs of Special
Interest to Boehringer Ingelheim, Pharmacovigilance
Unique Entry Point, which will subsequently report the
SAE to the Ethics Committee and local authorities.
Physical measurements
Anthropometric measurements are performed on each
participant at each study visit. Weight is measured with
the patient standing and then registered after rounding
it to the nearest 500 grams. Height is measured using a
metric tape with the patient standing against the wall,
and the value marked by a ruler placed horizontally on
the vertex of the patient’s head. BMI is estimated using
the weight in kilograms divided by the second power of
the height expressed in meters. Blood pressure is taken
using an automated sphygmomanometer Boso Medicus
Uno (Bosch & Sohn GmbH, Juningen, Germany) after a
5-min rest in sedentary body position. Number of beats
per min is measured from the radial artery by manual
palpation.
Measurement of flow-mediated dilatation (FMD) of the
brachial artery
Endothelium-dependent FMD following reactive hyperemia
and endothelium-independent nitroglycerin-mediated dila-
tation (NMD) following administration of glyceryl trinitrate
(GTN) are examined in the brachial artery by a trained
physician according to the guidelines described by Coretti
et al. [19]. Vasodilatation of the right brachial artery is mea-
sured using a 9–14 MHz, linear array, high-resolution
transducer (ACUSON S2000 ultrasound system, SIEMENS
Healthcare, 91052 Erlangen, Germany). After a 5-min rest
in the supine position the brachial artery is examined in a
longitudinal plane above the antecubital fossa by continu-
ous grayscale imaging in a segment with definitive intimal
interfaces between the lumen and the vascular wall. The
distance between the two intimal interfaces is measured at
least three times in the end-diastolic phase using echocar-
diographic (ECG). A blood pressure cuff is placed on the
forearm and inflated to a pressure of 250 mmHg for 5 min.
The postischemic diameter of the brachial artery is taken
45 s after cuff release. At least 15 min later, the diameter
between the two intimal lines is recorded immediately be-
fore and 3 min after sublingual administration of 0.4 mg
GTN. FMD diameter is calculated as the average of the
three diameter measurements following reactive hyperemia.
FMD and NMD are calculated as the percentage change in
diameter compared to baseline.
Meal Tolerance Test (MTT)
The MTT is performed after an overnight fast (apart
from water). A standard-gauge cannula is placed into a
subcutaneous vein for blood sampling. In order to
prevent blood clotting in the cannula and to keep the
cannula working it will be occasionally flushed with
sterile normal saline. Study medication will be given
(time −15 min) before the meal. A pre-meal blood sam-
ple will be taken (−5 min) and then all subjects are asked
to drink Fortimel compact (10 kcal/kg) over a period of
2 − 4 min (time 0 min). During the meal test further
blood samples will be taken at 15, 30, 60 and 120 min.
All samples are used for determination of glucose, insu-
lin and FFA levels. The blood at each time point is
placed into a fluoride oxalate tube (1 ml) for plasma glu-
cose and into a serum tube for insulin and FFA.
Laboratory measurements
Insulin and c-peptide will be measured by chemilumines-
cence on an ADVIA Centaur system (Siemens Healthcare
Diagnostics, Eschborn, Germany). Lipoproteins will be sep-
arated using a combined ultracentrifugation-precipitation
method (β-quantification). Cholesterol, triglyceride and
phospholipid levels will be determined enzymatically
(DiaSys, Holzheim, Germany). Apolipoprotein (apo) AI,
apo B and lipoprotein(a) levels will be measured by immu-
noturbidimetry (Greiner, Flacht, Germany). Lipoprotein
analyses will be performed on an Olympus AU640 analyzer
(Olympus Diagnostika, Hamburg, Germany). Free fatty
acids (FFA) will be measured enzymatically (Wako Chem-
ical, Neuss, Germany). Routine parameters will be deter-
mined using a cobas® analyzer (Roche Diagnostics,
Mannheim, Germany). Inflammatory markers, such as
sVCAM-1 and sICAM-1, will be measured by enzyme-
linked immunosorbent assays.
Arginine bioavailability ratios
L-arginine, L-citrulline and L-ornithine will be measured
using modifications of previously described chromato-
graphic methods [20, 21]. Briefly, after precipitation of
ethylenediaminetetraacetic acid (EDTA) plasma with
perchloric acid following neutralization of the super-
natant with sodium carbonate, the extracted amino acids
are derivatized with o-phthalaldehyde and separated on
a reversed phase column with gradient elution. Quantifi-
cation will be performed using ratios of the fluorescence
signals of the amino acids of interest to the internal
standard norvaline in comparison to the appropriated
calibration curves. Intra-assay and interassay CVs (coef-
ficient of variation) are all below 10 %. The global
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arginine bioavailability ratio (GABR) will be calculated
from L-arginine divided by the sum of (L-ornithine plus L-
citrulline). The L-arginine to L-ornithine ratio will be calcu-
lated by dividing the L-arginine by the L-ornithine levels.
Statistical considerations
A detailed Statistical Analysis Plan (SAP) will be pre-
pared. Before unblinding and locking the data for statis-
tical analysis, a review of all data will take place and the
SAP will be finalized and approved. Should the SAP and
this protocol differ, the methods in the SAP will prevail.
Definition of analysis populations
Study participants who withdraw their informed consent
are excluded from the study and will not be included in
any statistical analysis.
The analysis populations are defined as follows:
The ITT population will include all randomized
patients with a recorded primary outcome measure (i.e.,
the baseline and follow-up FMD measurement). All pa-
tients will be analyzed according to the randomized
treatment group. The primary analysis will be performed
on the ITT population.
The per-protocol population will consist of all patients
with recorded baseline and follow-up FMD measure-
ments and study medication compliance > 80 %. Non-
compliance is defined as missing 20 % or more doses of
trial medication during the 12-week treatment period.
The safety population will include all patients who re-
ceived at least one dose of the study medication. The
study participants will be analyzed according to the
treatment received.
General aspects
The analysis of the collected data in the study will be
performed using SAS v9.4. Continuous variables will be
presented as means, standard deviation (SD), median
and minimum and maximum; for categorical data, fre-
quencies and relative frequencies will be used.
Demographic and baseline characteristics
The demographic and baseline characteristics will be
summarized and compared between the groups
descriptively.
Analysis of the primary outcome
The primary outcome, the change in endothelial func-
tion measured by FMD at baseline and after 12 weeks of
treatment with linagliptin or placebo will be analyzed
using analysis of covariance (ANCOVA) with FMD at
week 12 as the dependent variable, and the baseline
FMD and treatment group as covariates. A two-sided p
value of < 0.05 is considered to indicate statistical
significance.
Analysis of the secondary outcomes
For the secondary outcomes, arginine bioavailability ra-
tios (GABR, arginine to ornithine ratio), biochemical
markers of endothelial function (sVCAM-1, sICAM-1)
and the evaluation of AUC of glucose, insulin and FFA
during the MTT, group comparisons will be performed
using parametric or nonparametric methods for un-
paired data (as appropriate). Comparisons within groups
will be performed using a paired t test or the Wilcoxon
rank-sum test.
Analysis of the safety parameters
Safety parameters will be summarized as interval or cat-
egorical summaries as appropriate. Listings and sum-
mary tables of AEs will be presented by treatment group
and relationship, seriousness and intensity.
Missing data handling
All available data will be used in the analysis and data
summaries. There will be no imputation of any missing
data. The reason that data are missing will be docu-
mented and reported.
Sample size
The sample size was estimated using the free calculator
available from http://www.quantitativeskills.com/sisa/
calculations/samsize.htm. For the sample size estimation
we assumed a relative 30 % improvement of endothelial
function in the linagliptin group and no changes from
baseline to week 12 in the placebo group. Although ef-
fect sizes and SDs vary substantially, we based our esti-
mation on a baseline FMD of approximately 5.0 % and a
SD of 1.5 % (absolute % FMD) [22] a total of 42 subjects
will be needed to detect this difference with a two-sided
alpha of 0.05 and a power of 0.90. For every subject
dropping out during the study (withdrawal of consent,
lost to follow-up) an additional subject will be enrolled
to make sure the trial is adequately powered. To con-
sider a dropout rate of approximately 15–20 %, we will
randomize a maximum of 50 subjects.
Data collection
Electronic Case Report Form (eCRF)
Study data will be captured on a web-based open source
eCRF (OpenClinica).
Characteristics at baseline and follow-up visits are
gathered: age, sex, weight, height, BMI, waist and hip
circumference, blood pressure, medical history, smoking
behavior, medication, FMD and MTT results. Privacy of
the patients is guaranteed; stored data and materials will
only be identifiable to the person by a sequentially
assigned subject number. The eCRF is designed in ac-
cordance with the requirements of the study protocol
and complies with regulatory requirements. Access to
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the eCRF is password-protected and the password is
only given to site personnel. Data generated throughout
the study are monitored, and the eCRFs are checked
against the subject records for accuracy and accuracy.
Following completion of the eCRFs, the data are checked
electronically for consistency and plausibility by prede-
fined range checks. If necessary, automatic queries are
generated for questionable data.
Data quality control
The research assistant and the investigators meet
monthly to review the study progress and procedures
and to discuss any AEs or dropouts. In view of the small
sample size, short study period and phase of the trial, a
Data Monitoring Committee, interim analysis and stop-
ping guidelines were not including in the trial design.
The data collection, management, analysis, interpret-
ation and production of publications is independent of
the funding bodies and other competing interests. The
trial results will be disseminated via journal publication
and conference presentation without exposing the iden-
tity of the trial subjects.
Monitoring
Monitoring is undertaken according to ICH Good Clin-
ical Practice guidelines and the study monitoring plan.
The study monitor is suitably trained, qualified and ex-
perienced to perform this task. Data are evaluated for
compliance with the protocol and accuracy in relation to
source documents. The following data are assessed:
Written informed consent
Flow chart filled in for included and excluded subjects
Trial progress
Primary and secondary outcome collection
Severe adverse events
Drug accountability of the study treatment
Discussion
A great variety of antidiabetic agents are available for
T2DM treatment. These treatments differ in their mech-
anisms of drug action and their long-term outcomes.
The FDA and the EMA require cardiovascular trials for
all new antihyperglycemic drugs in order to prove the
safety of these agents. Cardiovascular surrogate parame-
ters, such as endothelial function, cannot replace out-
come trials but are able to provide insights into the
potential mechanisms of the cardiovascular effects of
antihyperglycemic agents. Moreover, currently ongoing
trials do not specifically focus on early diabetes as a tar-
get of intervention and we therefore believe that our
study will contribute to a better understanding of cardio-
vascular effects of DPP-4 inhibitors in early diabetes.
Trial status
The trial is currently enrolling patients. As of 28
February 2016, 80 % of the patients have been en-
rolled in the study.
Additional file
Additional file 1: SPIRIT checklist. (PDF 74 kb)
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